Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.

PLoS One · 2012 · PMC3448662 · PMID 23029129

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Regarding safety, early safety reviews showed a trend towards increased mortality in patients receiving FCM, which led to a request for further data from the FDA [18] .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.